logo

For the Inventor, By the Inventor

Boulder, CO, United States of America

Ribozyme Pharmaceuticals, Incorporated


USPTO Granted Patents = 110


Forward Citations = 3,968

Loading Chart...
Loading Chart...

57 inventors (with patents filed for the assignee):

goldMedal Leonid Beigelman (41 out of 224 patents)

silverMedal Kenneth G Draper (33 out of 43 patents)

bronzeMedal James A McSwiggen (30 out of 99 patents)

4.  Nassim Usman (24 out of 32 patents)

5.  Jasenka Matulic-Adamic (20 out of 29 patents)

6.  Dan T Stinchcomb (19 out of 57 patents)

7.  James D Thompson (16 out of 19 patents)

8.  Alex Karpeisky (15 out of 17 patents)

9.  Alexander Karpeisky (14 out of 28 patents)

10.  Francine E Wincott (12 out of 17 patents)

11.  David Sweedler (9 out of 16 patents)

12.  Alex B Burgin (7 out of 8 patents)

13.  Sean M Sullivan (7 out of 10 patents)

14.  Thale Jarvis (6 out of 22 patents)

15.  Laurent Bellon (6 out of 8 patents)


Core Competencies:
Nucleic Acid Catalysts
Enzymatic Nucleic Acids
Nucleoside Analogues
Synthetic Ribonucleic Acids
Ribozyme Treatment
RNA Polymerase III
Nucleic Acid Inhibition
Nucleotides Incorporation
RNA Cleavage
Vascular Endothelial Growth Factor
Herpes Simplex Virus Inhibition
Hepatitis C Virus Replication

110 patents:

1. 6602858 - Nucleic acid catalysts comprising L-nucleotide analogs (2003-08-05),
2. 6586238 - Enzymatic nucleic acids containing 5′-and or 3′-cap structures (2003-07-01),
3. 6555668 - Non-nucleotide containing enzymatic nucleic acid (2003-04-29),
4. 6548657 - Method for screening nucleic acid catalysts (2003-04-15),
5. 6544755 - Method and reagent for treatment of diseases by expression of the c-Myc gene (2003-04-08),
6. 6528640 - Synthetic ribonucleic acids with RNAse activity (2003-03-04),
7. 6528639 - Base-modified enzymatic nucleic acid (2003-03-04),
8. 6509460 - Nucleoside triphosphates and their incorporation into oligonucleotides (2003-01-21),
9. 6506888 - 2′-O-amino-containing nucleoside analogs and polynucleotides (2003-01-14),
10. 6492512 - Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression (2002-12-10),
11. 6489465 - Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides (2002-12-03),
12. 6482932 - Nucleoside triphosphates and their incorporation into oligonucleotides (2002-11-19),
13. 6469158 - Synthesis, deprotection, analysis and purification of RNA and ribozymes (2002-10-22),
14. 6451540 - 2′-O-alkylthioalkyl and 2′-C-alkythioalkyl containing nucleic acids (2002-09-17),
15. 6448009 - Method for target site selection and discovery (2002-09-10),
Ribozyme Pharmaceuticals, incorporated is a leading biopharmaceutical company specialized in developing novel RNA-based therapeutics. We leverage the unique catalytic properties of ribozymes to create innovative drugs for a wide range of diseases, including genetic disorders, cancer, and viral infections. Our dedicated team of scientists and researchers work tirelessly to discover and optimize ribozyme-based therapies that have the potential to revolutionize healthcare. Visit our website to learn more about our cutting-edge developments and commitment to improving patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

110 Patents

#8 in Boulder, CO

#60 in Colorado

#3,347 in US

#6,948 in the World

...
Boulder, CO, United States of America

Ribozyme Pharmaceuticals, Incorporated

Forward Citations = 3,968

57 inventors:

goldMedal Leonid Beigelman (41 out of 224 patents)

silverMedal Kenneth G Draper (33 out of 43 patents)

bronzeMedal James A McSwiggen (30 out of 99 patents)

4.  Nassim Usman (24 out of 32 patents)

5.  Jasenka Matulic-Adamic (20 out of 29 patents)

Please report any incorrect information to support@idiyas.com
Loading…